Mateon Therapeutics Inc (MATN) financial statements (2021 and earlier)

Company profile

Business Address 29397 AGOURA RD.
AGUORA HILLS, CA 91301
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1100000
Cash and cash equivalents1100000
Receivables0000   
Prepaid expense    00 
Other undisclosed current assets0000  0
Total current assets:1100000
Noncurrent Assets
Property, plant and equipment0000   
Long-term investments and receivables    22 
Long-term investments    22 
Intangible assets, net (including goodwill)2222222266 
Goodwill2121212155 
Intangible assets, net (excluding goodwill)111111 
Other noncurrent assets 00    
Other undisclosed noncurrent assets1111  0
Total noncurrent assets:23232323770
TOTAL ASSETS:25242424880
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3222211
Accounts payable2222111
Accrued liabilities1100000
Employee-related liabilities      0
Debt111100 
Derivative instruments and hedges, liabilities1121   
Due to related parties011110 
Other undisclosed current liabilities43320 0
Total current liabilities:9887321
Noncurrent Liabilities
Total liabilities:9887321
Stockholders' equity
Stockholders' equity attributable to parent1516151756(1)
Preferred stock000000 
Common stock1111110
Additional paid in capital323131281312294
Accumulated deficit(18)(16)(17)(12)(9)(8)(296)
Stockholders' equity attributable to noncontrolling interest1      
Total stockholders' equity:1616151756(1)
TOTAL LIABILITIES AND EQUITY:25242424880

Income statement (P&L) ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Gross profit: 10    
Operating expenses(2)(1)(3)(1)(1)(1)(1)
Operating income (loss):(2)0(3)(1)(1)(1)(1)
Nonoperating income (expense)(0)1(2)(2)(0)00
Investment income, nonoperating  0  00
Interest and debt expense(0)(0)(1)(1)(0)(0) 
Net income (loss):(2)0(6)(4)(1)(1)(1)
Net loss attributable to noncontrolling interest(1)      
Other undisclosed net income attributable to parent10110  
Net income (loss) available to common stockholders, diluted:(2)1(5)(3)(1)(1)(1)

Comprehensive Income ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Net income (loss):(2)0(6)(4)(1)(1)(1)
Comprehensive income (loss):(2)0(6)(4)(1)(1)(1)
Comprehensive loss, net of tax, attributable to noncontrolling interest(1)      
Comprehensive income (loss), net of tax, attributable to parent:(3)0(6)(4)(1)(1)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: